bluuebunny/crossref_metadata_2025_split huggingface dataset:
A Novel Antimicrobial Stewardship Program-Guided Procalcitonin Initiative for Emergency Department Diagnosis of Bacterial Pneumonia in New York City
Authors: Rodriguez George D , Yashayev Roman , Yushuvayev Bella , Kula Anna , Warren Nathan , Dhillon Geeti , Tsapepas Demetra , Keane Caroline , Rodgers William H , Siegal Jonathan , Sharma Manish , Segal-Maurer Sorana 
Published: October 2017

Abstract

Background
An accurate diagnosis of bacterial pneumonia in the Emergency Department (ED) is challenging, resulting in inappropriate antibiotic use, adversely impacting patient care and safety. Procalcitonin (PCT), a serum biomarker, has good positive predictive value for bacterial lower respiratory tract infections. We sought to evaluate the impact of using PCT in an antimicrobial stewardship program (ASP)-driven algorithm to manage patients with presumed pneumonia in the ED.

Methods
We performed an IRB-approved quality initiative, 4-month retrospective evaluation of adult patients evaluated for pneumonia using PCT in a 515-bed university-affiliated hospital. Initial PCT use was restricted to ED for hemodynamically stable patients with presumed pneumonia. Subsequent PCT levels were ordered by ASP team members at 8- to 12-hours and days 3, 5, and 7 to guide the duration of antibiotic use and interpreted as per existing guidelines. Prior to start of initiative, aggressive education was provided by ASP to ED staff, followed by algorithm implementation. Outcomes included hospital admission, days of antibiotics, antibiotic use ≤48 hours, total PCT levels, length of stay, and 30-day pneumonia readmission.

Results
Baseline demographics of initial 182 patients differed between negative and positive PCT groups with age (78 vs. 84, P = 0.037) and sexfemale (88 vs. 15, P = 0.001). Negative PCT was associated with lower temperature (P = 0.0002), and white blood cell count (P = 0.0001) on admission (Figure 1). Patients with negative PCT had reduced antibiotic initiation (71% vs. 95%, P = 0.001) and were less likely to be admitted (89% vs. 98%, P = 0.078). A total of 460 PCT levels were collected [negative group: 303, median 2(2,2), positive group: 157, median 4(3,4)]. Patients with negative PCT had reduced antibiotic duration (P &lt; 0.001) and length of stay (P = 0.004) (Figures 2 and 3). There were no reported adverse events or differences in 30-day pneumonia readmissions.

Conclusion
Implementation of a PCT algorithm through ASP is a novel and efficacious addition to improving diagnostic yield, targeting appropriate therapy, and reducing length of stay. The impact on antibiotic resistance remains to be determined.

Disclosures
All authors: No reported disclosures.
Clinical Impact of Two Different Multiplex Respiratory Panel Assays on Management of Hospitalized Children Aged ≤24 months
Authors: Hassan Ferdaus , Lee Brian , Goldman Jennifer , Jackson Mary Anne , Selvarangan Rangaraj 
Published: October 2017

Abstract

Background
Highly multiplexed molecular assays are popular in clinical laboratories due their high sensitivity, specificity and relatively rapid turn-around time (TAT) for results. Luminex™ respiratory viral panel (RVP) detects 12 respiratory viruses, while BioFire™ respiratory panel (RP) detects 20 respiratory pathogens (17 viruses, 3 bacteria). The aim of the current study was to compare the impact of RVP and RP assay on management of hospitalized children aged ≤24 months.

Methods
Retrospective data were collected to compare the clinical impact from two multiplex molecular assays (RVP, December 2008–May 2012; RP August 2012–June 2015) on management and outcomes of hospitalized patients. Patients aged ≤24 months and positive for at least one respiratory virus were included. Patients who were (1) receiving immune suppressive therapy, (2) neonates requiring intensive care, or (3) hospitalized for &gt;7 days were excluded.

Results
A total of 810 patients in RVP and 2,095 patients in RP group were included. The median TAT for RVP and RP assay were 29 hours (IQR 26–58 hours) and 4 hours (IQR 2–8 hours), respectively (P &lt; 0.001). Significantly higher number of children in RVP group (44%, 357/810) received empiric antibiotic therapy compared with RP group (28%, 595/2095) (P &lt; 0.001). Following PCR test reporting, the rate of antibiotic discontinuation was higher in the RP group (23%, 135/595) vs. RVP group (16%, 56/357) (P &lt; 0.001). Antibiotics were discontinued more often in older children aged 6–24 months (23%, 113/492) compared with children aged &lt; 60 days (11%, 34/297) (P &lt; 0.001). Following positive influenza test results, more children received timely oseltamivir in the RP group (85%, 48/56) compared with the RVP group (17%, 7/41) (P &lt; 0.001). The median length of hospitalization (LOH) was shorter in the RP group (48 hours, IQR 32–76 hours) than in the RVP group (54 hours, IQR 39–89 hours) (P &lt; 0.001).

Conclusion
Rapid availability of test results from RP assay was associated with reduced antibiotic use, timely antiviral therapy and decreased LOH. The implementation of a more comprehensive respiratory multiplex molecular assay with rapid reporting of test results has the potential to improve management of hospitalized children, decrease unnecessary antibiotic therapy and reduce overall costs.

Disclosures
R. Selvarangan, BioFire Diagnostics: Board Member and Investigator, Consulting fee and Research grant; Luminex Diagnostics: Investigator, Research grant
Clinical Yield of Routine Use of Molecular Testing for Adult Outpatients with Diarrhea
Authors: Clark Stephen , Sidlak Michael , Mathers Amy , Poulter Melinda , Platts-Mills James 
Published: October 2017

Abstract

Background
Molecular diagnostics for enteropathogens increase yield while reducing turnaround time. However, many pathogens do not require specific therapy, and the cost is substantial.

Methods
We reviewed the use of the FilmArray GI Panel (BioFire Diagnostics, Salt Lake City, Utah) in adult outpatients at the University of Virginia and identified clinical features that could limit testing without reducing yield. We defined yield as (a) detection of a pathogen, (b) detection of a pathogen for which antimicrobial therapy is indicated, or (c) detection of a pathogen that can change management, which additionally included viral pathogens in immunocompromised patients.

Results
Between March 23, 2015 and February 25, 2016, we reviewed 452 tests from adult outpatients with diarrhea. A pathogen was detected in 88/452 (19.5%). The most common pathogens were: enteropathogenic E. coli (36; 8.0%), norovirus (17; 3.8%), Campylobacter (7, 1.5%), enteroaggregative E. coli (6, 1.3%), Giardia (6; 1.3%), and sapovirus (5; 1.1%). Based on clinical guidelines, antimicrobial treatment was clearly indicated for 19/452 subjects (4.2%). Limiting testing to patients with an additional enteric symptom (abdominal pain, nausea, vomiting, fecal urgency, tenesmus, or flatulence), a travel history, or an immunocompromising condition would reduce testing by 25.9%, with a treatable pathogen identified in 18/331 (5.4%) (sensitivity 94.7%, specificity 27.7%). Further modifying testing criteria to exclude subjects with vomiting, 18/288 (6.3%) had a treatable pathogen (sensitivity 94.7%, specificity 37.3%), and a pathogen which could change management was detected in 28/288 (9.7%) (sensitivity 96.6%, specificity 38.5%). Excluding immunocompromised subjects or those with a travel history, American College of Gastroenterology guidelines for testing were met by 293/348 (84.2%) with a documented duration of diarrhea, and a treatable pathogen was detected in 8/293 (2.7%) vs. 3/55 (5.5%) who did not meet testing guidelines.

Conclusion
Testing could be reduced by 36.3% without decreasing clinical yield by limiting testing to patients with diarrhea with an additional enteric symptom and no history of vomiting, a travel history, or an immunocompromising condition. ACG guidelines did not improve testing efficiency.

Disclosures
All authors: No reported disclosures.
Bare Below the Elbows: A Randomized Trial to Determine Whether Wearing Short-Sleeved Coats Reduces the Risk for Pathogen Transmission
Authors: John Amrita , Alhmidi Heba , Gonzalez-Orta Melany , Cadnum Jennifer , Donskey Curtis J 
Published: October 2017

Abstract

Background
Physician’s white coats are frequently contaminated, but seldom cleaned. Therefore, in the UK, a “bare below the elbows” dress code policy includes a recommendation that personnel wear short sleeves. However, it has not been demonstrated that wearing short sleeves reduces the likelihood of pathogen transmission.

Methods
We conducted a randomized, cross-over trial involving simulated patient care interactions to test the hypothesis that transmission of pathogens occurs less frequently when personnel wear short- vs long-sleeved coats. Healthcare personnel were randomized to wear either long- or short-sleeved white coats while examining a mannequin contaminated with cauliflower mosaic virus DNA followed by examination of an uncontaminated mannequin. We compared the frequency of transfer of the DNA marker with the sleeves and/or wrists and with the uncontaminated mannequin. During work rounds, physicians were observed to determine how often the sleeves of white coats contacted patients or the environment.

Results
During work rounds and simulated examinations, the sleeve cuff of long-sleeved coats frequently contacted the patient/mannequin or environment. Contamination with the DNA marker was detected significantly more often on the sleeves and/or wrists when personnel wore long- vs short-sleeved coats (5 of 20, 25% vs 0 of 20, 0%; P = 0.02). In one of five (20%) instances of sleeve and/or wrist contamination, the DNA marker was transferred to the second mannequin. It was also observed that healthcare personnel were less likely to include their wrist in handwashing between simulations if they were wearing long-sleeved coats.

Conclusion
During simulations of patient care, the sleeve cuff of long-sleeved white coats frequently became contaminated with a viral DNA marker that could be transferred. These results provide support for the recommendation that healthcare personnel wear short sleeves to reduce the risk for pathogen transmission.

Disclosures
All authors: No reported disclosures.
Obesity Following Antiretroviral Therapy (ART) Initiation is Common and Influenced by Both Traditional and HIV-/ART-Specific Risk Factors
Authors: Bakal David , Coelho Lara , Luz Paula M , Clark Jesse L , De Boni Raquel , Cardoso Sandra Wagner , Veloso Valdilea , Lake Jordan , Grinsztejn Beatriz 
Published: October 2017

Abstract

Background
Weight gain commonly occurs among HIV-infected (HIV+) adults initiating modern ART regimens, and obesity is increasingly reported in this population. However, data regarding specific risk factors for obesity development after ART initiation are conflicting.

Methods
We retrospectively analyzed data from a cohort of HIV+ adults who initiated ART between January 1, 2000 and December 31, 2015 in Rio de Janeiro, Brazil. Body mass index (BMI) was assessed at ART initiation. Participants who were non-obese (BMI &lt; 30kg/m2) at baseline and had ≥90 days of ART exposure were followed for development of obesity. Participants were censored at the time of obesity diagnosis or at end of follow-up (defined as death, loss to follow-up, end of study period or 2 years after their last weight measurement). Incidence rates were estimated using Poisson regression models and risk factor assessment was calculated using Cox regression models accounting for death and loss to follow-up as competing risks.

Results
Participants (n = 1,794) were 61.3% male, 48.3% white and had a median age of 36.3 years. At ART initiation, participants had a median BMI of 22.6kg/m2 and BMI category distribution was: underweight 14%, normal weight 56%, overweight 22% and obese 8%. Of the 1,567 non-obese participants followed after ART initiation, 76% gained weight, 44% increased their BMI category and 18% developed obesity. Median BMI at the end of follow-up was 24.7kg/m2 (0.4kg/m2 median annual change), the obesity incidence rate was 37.4 per 1000 person-years and the median time to obesity diagnosis was 1.9 years (vs. 4.7 years of follow-up for participants remaining non-obese). Factors associated with obesity after ART initiation included younger age at ART initiation, female sex, higher baseline BMI, lower baseline CD4+ T lymphocyte count, higher baseline HIV-1 RNA, having an integrase inhibitor as the most-used ART core drug and having diagnoses of hypertension and diabetes mellitus (Figure).

Conclusion
Obesity following ART initiation is frequent among HIV+ adults, with rates increasing in recent years. Both traditional (female sex) and HIV-specific (more advanced HIV disease, integrase inhibitor use) risk factors contribute importantly to obesity incidence following ART initiation.

Disclosures
All authors: No reported disclosures.
The Incidence of Hepatocellular Carcinoma Is not Increased in Individuals with Chronic Hepatitis C After Treatment with Interferon-free Regimens: an ERCHIVES Study
Authors: Li Darrick K , Ren Yanjie , Saikh Obaid , Fierer Daniel S , Re Vincent Lo , Abou-Samra Abdul-Badi , Chung Raymond T , Butt Adeel 
Published: October 2017

Abstract

Background
Sustained virologic response (SVR) after interferon-based treatment for chronic hepatitis C virus (HCV) infection has been strongly linked with decreased incidence of hepatocellular carcinoma (HCC). Surprisingly, several recent studies have reported higher rates of HCC in individuals treated with direct-acting antivirals (DAAs). However, making definitive conclusions has been challenging due to the heterogeneous populations and methodologies of these reports. As such, we sought to investigate whether DAA use is associated with increased rates of incident HCC.

Methods
Using the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) database, we identified 17,836 patients without a prior diagnosis of HCC and divided them into 3 groups based on treatment: (a) pegylated interferon and ribavirin (IFN) (n = 3,534); (b) DAA-based therapy (n = 5,734); and (c) an untreated control group (n = 8,468). Predictors of HCC were identified using multivariate Cox proportional hazards analysis. HCC-free survival in cirrhotics was assessed by Kaplan–Meier analysis.

Results
SVR was achieved by 66.6% and 96.2% of the IFN and DAA groups, respectively. In our cohort, the incidence rate of HCC was not different between IFN and DAA groups (7.48/1000 vs. 7.92/1000 patient-years of follow-up; P = 0.72). Moreover, DAA treatment was not associated with an increased risk of HCC (HR 1.16; [95% CI: 0.79, 1.71]) compared to IFN treatment. Other risk factors for HCC included older age, alcohol abuse/dependance history, smoking history, HCV genotype 3 infection, proton-pump inhibitor use, AFP &gt; 20, and cirrhosis. Notably, among cirrhotics who achieve SVR, HCC-free survival was not different between IFN and DAA treated groups, and both groups had significantly improved HCC-free survival compared with untreated patients.

Conclusion
Among cirrhotic patients with HCV, DAA treatment is associated with a comparable risk of HCC to IFN treatment. Furthermore, the rate of HCC after SVR by any treatment was significantly lower than for those untreated or who failed to achieve SVR. Previously reported increases in HCC associated with DAA treatment appear to be explained by the presence of pre-existing risk factors for HCC.

Disclosures
R. T. Chung, Gilead: Investigator, Research grant; Abbvie: Investigator, Research grant; Merck: Investigator, Research grant; Janssen: Investigator, Research grant; A. Butt, Merck: Investigator, Grant recipient
Antiviral Treatment among Hepatitis B Virus-Infected Pregnant Women—New York City and Michigan, 2013–2015
Authors: Link-Gelles Ruth , Koneru Alaya , Lazaroff Julie , Fineis Patrick , Nelson Noele , Schillie Sarah 
Published: October 2017

Abstract

Background
Individuals with chronic hepatitis B virus (HBV) infection are at increased risk for cirrhosis and hepatocellular carcinoma. Chronic HBV infection develops in 90% of persons infected at birth. Although postexposure prophylaxis (PEP), consisting of hepatitis B vaccine and immune globulin at birth, and completion of the three-dose vaccine series prevents up to 95% of perinatal HBV infections; however, breakthrough infections can occur, especially among infants born to women with high viral loads (VLs). Maternal antiviral treatment during pregnancy can reduce perinatal HBV transmission by 70% above the effect of infant PEP alone. We assessed factors associated with maternal antiviral treatment in a cohort of HBV-infected pregnant women with high VL.

Methods
During 2013–2015, the CDC-funded Supplemental Perinatal Hepatitis B Prevention Program collected information from interviews and medical charts of HBV-infected pregnant women in two sites. We assessed the association of demographic and clinical factors with maternal treatment in women with high VL (&gt;200,000 IU/mL), considering statistical significance at P &lt; 0.05.

Results
Among 1,521 women with maternal treatment and VL data, 151 (10%) had high VL. Among these 151 women, 66 (44%) received antiviral treatment (Table), all of whom were of Asian/Pacific Island race. None of the seven women of other races were treated (P = 0.02). Fifty-nine women (48%) receiving Medicaid were treated compared with six women (24%) who had private insurance (P = 0.04).

Conclusion
Mother’s race, country of birth, and insurance status were significantly associated with treatment in women with high VL. Because most women with high VL did not receive antiviral treatment during pregnancy, opportunities to reduce perinatal HBV transmission exist.

Disclosures
All authors: No reported disclosures.
Maternal Risk Factors Associated with Inadequate Testing and Loss to Follow-up in Infants with Perinatal Hepatitis C Virus Exposure
Authors: Bhardwaj Amrita , Mhanna Maroun , Abughali Nazha 
Published: October 2017

Abstract

Background
Lack of adequate testing and follow-up in infants born to hepatitis C virus (HCV) infected mothers continue to be a major challenge. There are multiple risk factors associated with this low rate of testing and follow-up including maternal, healthcare-related, and social factors. We sought to identify maternal risk factors that are associated with low HCV testing and follow-up in perinatally exposed infants.

Methods
In a retrospective cohort study, all HCV-infected pregnant women and their infants were reviewed. The study period expanded from June 1993 to May 2016. Medical records were reviewed for maternal characteristics and risk factors that could be associated with inadequate testing and loss to follow-up in infants with perinatal HCV exposure.

Results
During the study period, medical records of 407 mothers and their infants were reviewed. Only 26.5% (108/407) of all infants had adequate testing and follow-up for HCV. Among all infants, history of maternal intravenous drug use (IVDU) was significantly higher in infants with inadequate HCV testing than infants who were adequately tested [88% (193/218) vs. 76% (70/92) respectively; P = 0.005]. Infants who were adequately tested for HCV had a higher percentage of mothers on methadone maintenance therapy during pregnancy than infants who were not adequately tested [53% (35/66) vs. 34% (65/186) respectively; P = 0.010]. Also, infants with mothers who had HCV care were more likely to be adequately tested than infants whose mothers did not have HCV care [54% (56/102) vs. 41% (106/255), respectively; P = 0.022]. HCV transmission rate among infants with adequate testing was 11.1% (12/108).

Conclusion
Infants born to HCV infected mothers continue to have suboptimal testing. Maternal history of IVDU is associated with inadequate testing and loss to follow-up among infants exposed perinatally to HCV. Whereas, maternal methadone maintenance therapy during pregnancy, and maternal HCV medical care are associated with better follow-up. Screening pregnant women with HCV infection for history of IVDU and linking them to drug treatment centers as well as to HCV medical care may improve testing and follow-up in infants with perinatal HCV exposure.

Disclosures
All authors: No reported disclosures.
Prospective Surveillance and Rapid Whole-Genome Sequencing Detects Two Unsuspected Outbreaks of Carbapenemase-Producing Klebsiella pneumoniae in a UK Teaching Hospital
Authors: Torok Estee , Brodrick Hayley , Khokhar Fahad , Blane Beth , Polgarova Petra , Brown Joanne , Enoch David , Brown Nicholas , Summers Charlotte , Preller Jacobus , Thomson Nick , Dougan Gordon , Parkhill Julian , Peacock Sharon 
Published: October 2017

Abstract

Background
The increasing incidence of carbapenemase-producing Enterobacteriaceae (CPE) is a global health concern, as treatment options are extremely limited. The prevalence of CPE in UK hospitals is unknown, as national screening guidelines only recommend screening in patients considered to be at high-risk of CPE. Patients in intensive care units (ICU) are at high-risk of healthcare-associated infections caused by multidrug-resistant organisms (MDRO).

Methods
We conducted a six-month prospective surveillance study to determine the prevalence of MDRO in a UK teaching hospital ICU. Between June and December 2016, all adult patients admitted to ICU were screened for MDRO on admission, on discharge, and weekly during their ICU stay. Surveillance samples included stool or rectal swabs, urine, sputum or tracheal aspirates, and wound swabs (if wounds were present). Isolates were characterized phenotypically before undergoing whole-genome sequencing (WGS), epidemiological, and phylogenetic analyses.

Results
During the first week of the study we identified stool carriage of a multidrug-resistant Klebsiella pneumoniae strain in two patients neither of whom had recognized risk factors for CPE. Both isolates were resistant to all antibiotics tested, apart from colistin, and were PCR-positive for the blaNDM-1 gene. Enhanced surveillance by the infection control team identified four additional patients in several wards who had stool carriage (n = 3) or bloodstream infection (n = 1) with a blaNDM-1K. pneumoniae isolate. Epidemiological links were identified between these six patients. Five months later, a second outbreak of multidrug-resistant K. pneumoniae was detected, involving stool carriage by four patients on two different wards. Environmental screening identified environmental contamination with multidrug-resistant K. pneumoniae on one ward. DNA sequence analysis confirmed that a novel blaNDM-1K. pneumoniaelineage (ST78) was responsible for both outbreaks in the hospital.

Conclusion
We identified two unsuspected blaNDM-1K. pneumoniae outbreaks in patients with no recognized risk factors for CPE. This highlights the importance of prospective surveillance for MDRO in high-risk settings, such as ICUs, and supports the use of rapid WGS to support outbreak investigations in real-time.

Disclosures
All authors: No reported disclosures.